The National Institute of Allergy and Infectious Diseases (NIAID) supports a comprehensive portfolio of contract resources to discover and develop novel therapeutic agents for the prevention and treatment of infections caused by Human Immunodeficiency Virus-1 (HIV-1), AIDS-associated opportunistic pathogens, and other infectious agents. Animal model resources constitute one element of this drug discovery and development program. The purpose of the present project is to provide a resource for evaluating potential therapeutics for HIV-1 infection. Details regarding access by the scientific community are provided at: www.niaid.nih.gov/daids/pdatguide/overview.htm The contractor is responsible for i) evaluating therapeutic agents, alone and in combination, for efficacy and toxicity in vitro and in the SCID-hu thymus/liver animal model; ii) performing quality assurance/control of the components of the in vitro and in vivo assay systems, to insure reproducible evaluation of candidate therapies; iii) determining optimal routes and schedules of administration; iv) modifying the model system as necessary, to augment its usefulness for evaluating potential HIV-1 therapeutics; and 5) preparing and submitting periodic and interim reports.
|Favre, David; Stoddart, Cheryl A; Emu, Brinda et al. (2011) HIV disease progression correlates with the generation of dysfunctional naive CD8(low) T cells. Blood 117:2189-99|
|Xie, Dong; Yao, Cheng; Wang, Li et al. (2010) An albumin-conjugated peptide exhibits potent anti-HIV activity and long in vivo half-life. Antimicrob Agents Chemother 54:191-6|
|Stoddart, Cheryl A; Keir, Mary E; McCune, Joseph M (2010) IFN-alpha-induced upregulation of CCR5 leads to expanded HIV tropism in vivo. PLoS Pathog 6:e1000766|
|Stoddart, Cheryl A; Nault, Genevieve; Galkina, Sofiya A et al. (2008) Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice. J Biol Chem 283:34045-52|
|Stoddart, Cheryl A; Bales, Cheryl A; Bare, Jennifer C et al. (2007) Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals. PLoS One 2:e655|
|Stoddart, Cheryl A; Joshi, Pheroze; Sloan, Barbara et al. (2007) Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice. PLoS One 2:e1251|